trending Market Intelligence /marketintelligence/en/news-insights/trending/O_9pgk5mLA5Pw0w4D6wPmg2 content esgSubNav
In This List

Stryker to buy Entellus Medical in $662M deal

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Stryker to buy Entellus Medical in $662M deal

Stryker Corp. agreed to buy medical device maker Entellus Medical, Inc. for an equity value of about $662 million.

Entellus Medical specializes in making minimally invasive devices for procedures related to ear, nose and throat, or ENT.

Under the deal, which would complement Stryker's existing ENT portfolio, the company would pay Entellus' shareholders $24 per share.

The closing of this transaction is subject to approval by Entellus' stockholders, expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions.

The deal is expected to be dilutive to Stryker's 2018 adjusted net earnings per diluted share by about 4 cents and accretive thereafter.

Guggenheim Securities acted as financial adviser and Skadden Arps Slate Meagher & Flom LLP served as outside legal counsel to Stryker for the deal.